^
Association details:
| Biomarker: | BRCA2 mutation |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | Yondelis (trabectedin) (Alkylating agent, DNA inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
830P - Subanalysis of a randomized phase III study comparing trabectedin and PLD vs PLD alone in patients with recurrent ovarian cancer (ROC)
Published date:
09/14/2020
Excerpt:
Among all patients included in the study, only 57.8% were PS after the last platinum, precluding a reliable estimation of PFS or OS. Despite that, there is a trend toward improved PFS combined with significant improvement in ORR with trabectedin/PLD in this subset of patients. More pronounced benefits were observed in PS patients with a PFI 6-12 months and PS patients with BRCA 1/2 mutations.
Secondary therapy:
pegylated liposomal doxorubicin
Trial ID:
Source:
Title:
Study With Trabectedin in BRCA1 and BRCA2 Mutation Carrier and BRCAness Phenotype Ovarian Cancer
Excerpt:
...high-grade serous cancers, great initial sensitivity to platinum drugs and retention of platinum-sensitivity through multiple relapses, long history of disease, long survival, long TFIs between relapses (patients with high personal risk factors will be included after doing the analysis for BRCA 1-2 mutation before knowing the results)....
Trial ID:
Source:
Title:
Phase II study aiming at evaluating activity of Yondelis in recurrent ovarian cancer patients with BRCA mutation Studio clinico di fase 2 finalizzato a valutare l'attivita' dello Yondelis nelle pazienti con recidiva di carcinoma dell'ovaio con la mutazione genetica BRCA.
Excerpt:
...Patients with partially platinum sensitive ovarian cancer (platinum-free interval 6-12 months) who have previously received at least two platinum based chemotherapy lines, BRCA mutated or with BRCAness phenotype Definition of BRCAness phenotype: high-grade serous cancers, great initial sensitivity to platinum drugs and retention of platinum-sensitivity through multiple relapses, long history of disease, long survival, long TFIs between relapses (patients with high personal risk factors will be included after doing the analysis for BRCA 1-2 mutation before knowing the results). ...
Trial ID:
